EXELIXIS INC's ticker is EXEL and the CUSIP is 30161Q104. A total of 147 filers reported holding EXELIXIS INC in Q1 2016. The put-call ratio across all filers is 0.36 and the average weighting 0.5%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $11,724,846 | -10.6% | 521,800 | -5.6% | 0.01% | -11.1% |
Q1 2024 | $13,110,825 | -3.2% | 552,500 | -2.2% | 0.01% | -10.0% |
Q4 2023 | $13,547,153 | -3.8% | 564,700 | -12.3% | 0.01% | -9.1% |
Q3 2023 | $14,075,770 | +16.0% | 644,200 | +1.4% | 0.01% | +37.5% |
Q2 2023 | $12,134,850 | -10.2% | 635,000 | -8.8% | 0.01% | -11.1% |
Q1 2023 | $13,513,242 | +8.4% | 696,200 | -10.4% | 0.01% | 0.0% |
Q4 2022 | $12,464,684 | +4.5% | 777,100 | +2.2% | 0.01% | 0.0% |
Q3 2022 | $11,926,000 | -23.9% | 760,600 | +1.1% | 0.01% | -18.2% |
Q2 2022 | $15,665,000 | -7.6% | 752,400 | +0.6% | 0.01% | +10.0% |
Q1 2022 | $16,962,000 | +33.9% | 748,200 | +7.9% | 0.01% | +25.0% |
Q4 2021 | $12,672,000 | -13.4% | 693,200 | +0.1% | 0.01% | -11.1% |
Q3 2021 | $14,637,000 | +16.8% | 692,400 | +0.7% | 0.01% | +12.5% |
Q2 2021 | $12,530,000 | -21.7% | 687,700 | -3.0% | 0.01% | -27.3% |
Q1 2021 | $16,012,000 | +14.2% | 708,800 | +1.5% | 0.01% | +10.0% |
Q4 2020 | $14,021,000 | -17.5% | 698,600 | +0.5% | 0.01% | -23.1% |
Q3 2020 | $16,993,000 | +5.0% | 695,000 | +1.9% | 0.01% | -7.1% |
Q2 2020 | $16,186,000 | +59.5% | 681,800 | +15.7% | 0.01% | +27.3% |
Q1 2020 | $10,148,000 | -0.7% | 589,300 | +1.6% | 0.01% | +10.0% |
Q4 2019 | $10,218,000 | +1.8% | 579,900 | +2.1% | 0.01% | -9.1% |
Q3 2019 | $10,042,000 | -15.9% | 567,800 | +1.7% | 0.01% | -15.4% |
Q2 2019 | $11,935,000 | -8.0% | 558,500 | +2.5% | 0.01% | -7.1% |
Q1 2019 | $12,969,000 | +25.1% | 544,900 | +3.4% | 0.01% | +7.7% |
Q4 2018 | $10,366,000 | +13.6% | 527,000 | +2.4% | 0.01% | +30.0% |
Q3 2018 | $9,122,000 | -17.7% | 514,800 | 0.0% | 0.01% | -23.1% |
Q2 2018 | $11,078,000 | -2.9% | 514,800 | 0.0% | 0.01% | -7.1% |
Q1 2018 | $11,403,000 | -25.1% | 514,800 | +2.8% | 0.01% | -12.5% |
Q4 2017 | $15,218,000 | +28.4% | 500,600 | +2.3% | 0.02% | +23.1% |
Q3 2017 | $11,853,000 | -1.2% | 489,200 | +0.5% | 0.01% | -7.1% |
Q2 2017 | $11,992,000 | +23.4% | 486,900 | +8.6% | 0.01% | +16.7% |
Q1 2017 | $9,717,000 | +72.1% | 448,400 | +18.4% | 0.01% | +33.3% |
Q4 2016 | $5,646,000 | +20.2% | 378,700 | +3.1% | 0.01% | +12.5% |
Q3 2016 | $4,698,000 | +66.3% | 367,300 | +1.5% | 0.01% | +60.0% |
Q2 2016 | $2,825,000 | +102.5% | 361,700 | 0.0% | 0.01% | +66.7% |
Q1 2016 | $1,395,000 | -12.0% | 361,700 | +28.6% | 0.00% | -25.0% |
Q4 2015 | $1,586,000 | +0.5% | 281,200 | 0.0% | 0.00% | 0.0% |
Q3 2015 | $1,578,000 | +89.7% | 281,200 | +27.0% | 0.00% | +100.0% |
Q2 2015 | $832,000 | +54.1% | 221,400 | +5.3% | 0.00% | +100.0% |
Q1 2015 | $540,000 | +78.2% | 210,300 | 0.0% | 0.00% | 0.0% |
Q4 2014 | $303,000 | -5.9% | 210,300 | 0.0% | 0.00% | 0.0% |
Q3 2014 | $322,000 | -55.7% | 210,300 | -1.9% | 0.00% | -66.7% |
Q2 2014 | $727,000 | -4.2% | 214,400 | 0.0% | 0.00% | 0.0% |
Q1 2014 | $759,000 | -22.2% | 214,400 | +34.8% | 0.00% | -25.0% |
Q4 2013 | $975,000 | +5.3% | 159,100 | 0.0% | 0.00% | 0.0% |
Q3 2013 | $926,000 | +21.5% | 159,100 | -5.2% | 0.00% | +33.3% |
Q2 2013 | $762,000 | – | 167,800 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Meditor Group Ltd | 11,275,871 | $254,722,000 | 71.55% |
GREAT POINT PARTNERS LLC | 1,201,100 | $27,133,000 | 5.61% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 886,534 | $20,027,000 | 5.30% |
Sargent Investment Group, LLC | 498,350 | $11,258,000 | 2.96% |
CAPITAL MANAGEMENT CORP /VA | 311,660 | $7,040,000 | 1.57% |
EULAV Asset Management | 2,460,000 | $55,571,000 | 1.49% |
CM Management, LLC | 80,000 | $1,807,000 | 1.34% |
Integral Health Asset Management, LLC | 200,000 | $4,518,000 | 1.29% |
FARALLON CAPITAL MANAGEMENT LLC | 10,750,000 | $242,843,000 | 1.21% |
Sofinnova Investments, Inc. | 839,181 | $18,957,000 | 1.14% |